MedTrace Logo

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

NCT05894707 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-06-08

No results posted yet for this study

Summary

The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.

Conditions

Interventions

DRUG

SCT650C

Recombinant anti-IL-17A antibody

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam Salman · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-11-30
Completion
2024-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05894707 on ClinicalTrials.gov